Hydrocortisone Market Report 2026

The hydrocortisone market size has grown strongly in recent years. It will grow from $1.62 billion in 2025 to $1.72 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to widespread use of corticosteroids in inflammatory diseases, strong physician familiarity with hydrocortisone therapy, availability of generic formulations, increasing prevalence of skin disorders, established role in adrenal insufficiency treatment.

The hydrocortisone market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising incidence of autoimmune and respiratory diseases, growing self-medication through otc creams, development of improved delivery systems, expanding geriatric population, increased access through online pharmacies. Major trends in the forecast period include growing demand for topical corticosteroids in dermatology, increasing use of low-dose and otc hydrocortisone products, expansion of hydrocortisone use in chronic inflammatory disorders, rising adoption of extended-release oral formulations, focus on safer long-term corticosteroid therapies.

The increasing prevalence of inflammatory and autoimmune diseases is expected to drive the growth of the hydrocortisone market in the coming years. Inflammatory and autoimmune conditions occur when the immune system mistakenly attacks the body’s tissues, resulting in chronic inflammation and tissue damage. The rising adoption of treatments for these conditions is supported by the growing prevalence of the diseases and advancements in medical therapies. Hydrocortisone is commonly used to manage inflammatory and autoimmune diseases, such as severe asthma exacerbations, by reducing airway inflammation and improving breathing, often administered intravenously in emergency situations. For example, in August 2024, Public Health Scotland reported that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients in 2023. Consequently, the increasing prevalence of inflammatory and autoimmune diseases is propelling the hydrocortisone market.

The growth of the aging population is also expected to contribute to the expansion of the hydrocortisone market. An aging population refers to a rising proportion of older individuals in society, driven by increased life expectancy and declining birth rates. As healthcare advances extend longevity, the elderly increasingly require treatments to manage inflammation and chronic conditions, such as arthritis, adrenal insufficiency, and skin disorders. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that Americans aged 65 and older are projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the total U.S. population is expected to grow from 17% to 23% over the same period. Therefore, the expanding elderly population is driving demand for hydrocortisone treatments.

Key companies in the hydrocortisone market are focusing on combination therapies, such as hydrocortisone combined with butyrate, to improve treatment outcomes and expand product portfolios. Hydrocortisone-butyrate lotions leverage the anti-inflammatory properties of hydrocortisone along with butyrate’s immunomodulatory effects and potential to enhance skin barrier function, offering a synergistic approach to managing skin conditions. For example, in November 2023, J. Molner AS., an Estonia-based pharmaceutical company, launched Hydrocortisone Butyrate Lotion 0.1% in the United States, marking a strategic milestone in expanding its global commercial platform. The lotion is intended to treat inflammatory skin conditions and reflects Molner’s commitment to increasing its international market presence.

Major companies operating in the hydrocortisone market are Pfizer Inc., Johnson & Johnson, Bayer AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Macleods Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Taro Pharmaceutical Industries Ltd., Lannett Company Inc., Almirall SA, Leo Pharma AS, Perrigo Company plc, Recordati S.p.A.

North America was the largest region in the hydrocortisone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hydrocortisone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hydrocortisone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the hydrocortisone market by increasing costs associated with imported active pharmaceutical ingredients, excipients, and pharmaceutical packaging materials. These impacts are most pronounced in injectable and tablet segments and in regions dependent on cross-border API sourcing, particularly North America and parts of Europe. However, tariffs are also encouraging manufacturers to localize API production, strengthen domestic supply chains, and improve manufacturing efficiency, supporting long-term market stability.

The hydrocortisone market research report is one of a series of new reports that provides hydrocortisone market statistics, including hydrocortisone industry global market size, regional shares, competitors with a hydrocortisone market share, detailed hydrocortisone market segments, market trends and opportunities, and any further data you may need to thrive in the hydrocortisone industry. This hydrocortisone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hydrocortisone is a corticosteroid hormone naturally produced by the adrenal glands, playing a key role in regulating metabolism and immune responses. It is also synthetically produced for medical use, primarily as an anti-inflammatory agent, and is often applied topically to alleviate skin inflammation and itching.

The main types of hydrocortisone products include creams, injections, and tablets. Cream formulations are topical medications applied directly to the skin to reduce inflammation, irritation, and itching caused by conditions such as eczema, dermatitis, and insect bites. Hydrocortisone can be administered via topical, oral, or parenteral routes and is used to manage a variety of conditions, including adrenocortical dysfunction, adrenergic syndrome, hypercalcemia, thyroiditis, rheumatoid arthritis, dermatitis, asthma, chronic obstructive pulmonary disease, and others. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The hydrocortisone market consists of sales of hydrocortisone creams, ointments, lotions, and oral formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.